TG003: Precision Clk1/2 Inhibition Driving Splice Therapy...
2025-10-19
Explore how TG003, a selective Cdc2-like kinase inhibitor, is redefining alternative splicing modulation and cancer research targeting Clk2. This in-depth article uniquely examines TG003’s biochemical selectivity, mechanistic insights, and its distinct translational potential for exon-skipping therapy and combating platinum resistance.